This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Pegaptanib sodium injections (0.3mg intravitreally every six weeks) and ranibizumab injections (0.5mg intravitreally every month) for two years were each compared with PDT using verteporfin (up to every three months), which was the usual care in the study setting.
Location/setting
USA/secondary care.
Methods

Analytical approach:
: A state-transition model was used to estimate the clinical and economic outcomes of the alternative treatments. The model was based on one reported in Sharma, et al. (2001, see ' Other Publications of Related Interest' below for bibliographic details). The model were evaluated three lesion types separately; predominantly classic, minimally classic, and occult with no classic lesions. The time horizon was two years and the authors stated that the perspective was that of the third-party payer.
Effectiveness data:
The effectiveness evidence was from randomised controlled trials that assessed the effectiveness of the treatments compared with control or sham treatment. The main clinical parameter was the visual acuity gain or loss measured by a gain or loss of 15 letters on a vision test. These trials also provided evidence for the frequency and dose of treatments.
Monetary benefit and utility valuations:
The utility estimates, for the clinical outcomes, were based on published time trade-off values. The disutilities associated with complications were from a combination of published values and expert opinion.
Measure of benefit:
The measure of benefit was the number of quality-adjusted life-years (QALYs), which were discounted at an annual rate of 3%.
